Wells Fargo raised the firm’s price target on Halozyme to $58 from $48 and keeps an Overweight rating on the shares. The firm adjusted its model for the company’s updated royalties post the new European Union patent. Halozyme’s new patent seems to be a manufacturing related patent which covers manufacturing of the product using a specific process, the analyst tells investors in a research note. The company said that approved, and pipeline products within Wave’s 1/2/3 have collaboration patents granted or pending, and is confident in patents pending, Wells points out.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
- Halozyme granted European patent covering ENHANZE drug delivery platform
- Halozyme and Bristol Myers’ combination receives updated FDA action date
- Halozyme price target raised to $45 from $39 at Leerink
- Halozyme price target lowered to $71 from $72 at JMP Securities